(MENAFN- PR Newswire)
First clinical data from ongoing Phase 1/2 trial show dose-dependent anti-tumor activity for investigational REGN5678 (PSMAxCD28) when combined with standard dose Libtayo, suggesting potential to overcome mCRPC resistance to PD-1 inhibition
Anti-cancer activity correlated with immune-related adverse events
These data provide early evidence and proof of principle for Regeneron’s broader costimulatory bispecific platform, which includes three CD28 bispecifics in ongoing clinical trials and additional candidates in preclinical development
TARRYTOWN, N.Y., Aug. 3, 2022 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced encouraging initial data from an ongoing Phase 1/2 trial investigating REGN5678, a novel PSMAxCD28 costimulatory bispecific antibody, in combination with the company’s…
